RxDoctor Payments Data

Shavon Prentice, APRN

Family · Louisville, KYNPI 1962782128

Payments from drug & device makers

$486in general payments, 2019–2025

Across 23 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$112
  • Novartis$107
  • Vanda Pharmaceuticals Inc.$47
  • Lilly USA, LLC$40
  • Neurocrine Biosciences, Inc.$29
  • GSK$28
  • plus $123 from 7 others

What the payments were for

  • Food & beverage$486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$486 in reported general payments places this provider in the 50th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,736
Medicare patients
18
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$38,569
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$17,581
JardianceEmpagliflozin12$12,592
OzempicSemaglutide11$12,273
Spiriva RespimatTiotropium Bromide14$10,386
SymbicortBudesonide/Formoterol Fumarate14$6,303
Albuterol Sulfate HfaAlbuterol Sulfate39$1,112
Atorvastatin Calcium167$972
Duloxetine Hcl51$786
Tamsulosin Hcl50$717
Buspirone Hcl26$664
Ropinirole Hcl18$663
FenofibrateFenofibrate Nanocrystallized14$633
Bumetanide23$615
Potassium Chloride43$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$28$17,58113 claims
Novo NordiskOzempic$112$12,27311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →